goetzpartners advised EUSA Pharma

On May 9th 2017, EUSA Pharma announced that the European commission approved dinutuximab beta as the only immunotherapy for the treatment of high-risk neuroblastoma. Neuroblastoma is an orphan oncology indication with significant unmet medical need. It accounts for up to 10% of childhood tumors and affects approximately 1,200 children in the EU and US each year. Dinutuximab beta already received a positive CHMP (Committee for Medicinal Products for Human Use) opinion in March 2017, with the recommendation to grant a marketing authorization under exceptional circumstances for the treatment of high-risk neuroblastoma in Europe.

EUSA Pharma acquired the global rights to cancer treatment dinutuximab beta (APN311) from Apeiron Biologics in 2016. Under the terms of the agreement, EUSA Pharma paid Apeiron an upfront fee, with a portion contingent on EU approval. EUSA Pharma will furthermore pay regulatory milestone payments in other key territories and royalties on future products sales.

Fortlane Partners Corporate Finance Ltd introduced the opportunity to EUSA Pharma and acted as sole financial advisor to EUSA Pharma in the acquisition of global rights of dinutuximab beta.

About EUSA Pharma

EUSA Pharma is an international, specialty pharmaceutical company with a focus on oncology and oncology support, which is considerably strengthened by the market approval of dinutuximab beta. The company owns a broad portfolio of approved and named-patient specific hospital products.

Apeiron is a private biotech company based in Vienna with a focus on the development of immunological therapies targeting cancer. Their lead product APN311 is a monoclonal antibody for the treatment of neuroblastoma.

Transaction team:

Ulrich Kinzel
Managing Director
 

Dr. Melina Reisenberg
Associate